Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor.

Kurobe M, Kawai K, Oikawa T, Ichioka D, Kandori S, Takaoka E, Kojima T, Joraku A, Suetomi T, Miyazaki J, Nishiyama H.

J Cancer Res Clin Oncol. 2015 Jan;141(1):127-33. doi: 10.1007/s00432-014-1760-x. Epub 2014 Jul 26.

2.

Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.

Park S, Lee S, Lee J, Park SH, Park JO, Kang WK, Park YS, Lim HY.

Onkologie. 2011;34(8-9):416-20. doi: 10.1159/000331129. Epub 2011 Aug 23.

PMID:
21934340
3.

Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer.

Kawai K, Miyazaki J, Tsukamoto S, Hinotsu S, Hattori K, Shimazui T, Akaza H.

Jpn J Clin Oncol. 2003 Mar;33(3):127-31.

PMID:
12672789
4.

Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.

Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J, Bosl GJ, Motzer RJ.

J Clin Oncol. 2005 Sep 20;23(27):6549-55.

PMID:
16170162
5.

Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors: a single-center experience.

Kosmas C, Athanasopoulos A, Dimitriadis G, Miltiadous C, Zilakos M, Lydakis D, Magiorkinis E, Gekas C, Daladimos T, Mylonakis N, Ziras N.

Anticancer Drugs. 2014 Aug;25(7):841-7. doi: 10.1097/CAD.0000000000000100.

PMID:
24625457
6.

Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support.

Broun ER, Nichols CR, Turns M, Williams SD, Loehrer PJ, Roth BJ, Lazarus HM, Einhorn LH.

Cancer. 1994 Mar 15;73(6):1716-20.

7.

Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience.

Motzer RJ, Bajorin DF, Vlamis V, Weisen S, Bosl GJ.

Semin Oncol. 1992 Dec;19(6 Suppl 12):8-11.

PMID:
1336624
8.

Salvage chemotherapy with docetaxel, ifosfamide and nedaplatin (DIN) for patients with advanced germ cell tumors: a preliminary report.

Yamada S, Saito H, Ohara S, Yamashita S, Mitsuzuka K, Namiki S, Miyazato M, Kaiho Y, Ito A, Nakagawa H, Ishidoya S, Arai Y.

Jpn J Clin Oncol. 2013 Jul;43(7):734-9. doi: 10.1093/jjco/hyt060. Epub 2013 Apr 25.

PMID:
23619987
9.

The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors.

Motzer RJ, Cooper K, Geller NL, Bajorin DF, Dmitrovsky E, Herr H, Morse M, Fair W, Sogani P, Russo P, et al.

Cancer. 1990 Dec 15;66(12):2476-81.

10.

Methotrexate, etoposide, ifosfamide and cisplatin (MVIP): An effective salvage therapy for patients with refractory or relapsed germ-cell tumors.

Potamianou A, Ziras N, Bountouroglou N, Varthalitis J, Karvounis N, Pectasidis D, Athanassiou AE.

J BUON. 2002 Oct-Dec;7(4):337-45.

PMID:
17955577
11.

[Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].

Zhou SY, Shi YK, He XH, Zhang P, Dong M, Huang DZ, Yang JL, Zhang CG, Liu P, Yang S, Feng FY.

Ai Zheng. 2005 Apr;24(4):465-9. Chinese.

PMID:
15820071
12.

Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors.

Nonomura N, Oka D, Nishimura K, Nakayama M, Inoue H, Mizutani Y, Miki T, Okuyama A.

Int J Urol. 2007 Jun;14(6):527-31.

13.

Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.

Frasci G, D'Aiuto G, Comella P, Apicella A, Thomas R, Capasso I, Di Bonito M, Cartenì G, Biglietto M, De Lucia L, Maiorino L, Piccolo S, Bianchi U, D'Aniello R, Lapenta L, Comella G.

Breast Cancer Res Treat. 1999 Aug;56(3):239-52.

PMID:
10573115
14.
15.

Salvage chemotherapy with paclitaxel and gemcitabine plus nedaplatin (TGN) as part of multidisciplinary therapy in patients with heavily pretreated cisplatin-refractory germ cell tumors.

Shiraishi T, Nakamura T, Mikami K, Takaha N, Kawauchi A, Miki T.

Int J Clin Oncol. 2009 Oct;14(5):436-41. doi: 10.1007/s10147-009-0899-y. Epub 2009 Oct 25.

PMID:
19856053
16.
17.

Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.

Hartmann JT, Gauler T, Metzner B, Gerl A, Casper J, Rick O, Horger M, Schleicher J, Derigs G, Mayer-Steinacker R, Beyer J, Kuczyk MA, Bokemeyer C; German Testicular Cancer Study Group..

J Clin Oncol. 2007 Dec 20;25(36):5742-7.

PMID:
18089869
18.

Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy.

Ronnen EA, Kondagunta GV, Bacik J, Marion S, Bajorin DF, Sheinfeld J, Bosl GJ, Motzer RJ.

J Clin Oncol. 2005 Oct 1;23(28):6999-7004.

PMID:
16192587
19.

Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.

Frasci G, Comella P, D'Aiuto G, Budillon A, Barbarulo D, Thomas R, Capasso I, Casaretti R, Daponte A, Caponigro F, Gravina A, Maiorino L, Caratení G, Gentile A, Comella G.

Breast Cancer Res Treat. 1998 May;49(1):13-26.

PMID:
9694607
20.

Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.

Narayan V, Gunnarsson O, Hwang WT, Squillante CM, Nathanson KL, Stadtmauer EA, Vaughn DJ.

Clin Genitourin Cancer. 2016 Dec;14(6):524-529. doi: 10.1016/j.clgc.2016.03.015. Epub 2016 Mar 24.

PMID:
27083130

Supplemental Content

Support Center